LifeVantage Announces Financial Results for First Quarter Fiscal 2027

SALT LAKE CITY, Utah – LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its quarter ended September 30, 2026.

First Quarter Fiscal 2027 Summary*:

• Revenue was $37.1 million, a decrease of 22.0% from the prior year period;
• Revenue in the Americas decreased 22.2%, and revenue in Asia/Pacific & Europe decreased 21.2%;
• Net loss per diluted share was $0.02, versus net income per diluted share of $0.17 a year ago;
• Adjusted earnings per diluted share was $0.05, compared to $0.18 a year ago; and
• Adjusted EBITDA was $1.9 million compared to $3.9 million a year ago.

* All comparisons are on a year over year basis and compare the fourth quarter of fiscal 2027 to the fourth quarter of fiscal 2026, unless otherwise noted.

“Despite a challenging quarter, LifeVantage has significant untapped potential, and we now have a clear strategy designed to capture it,”

said Terrence Moorehead, President and Chief Executive Officer.

“Our focus is on transforming LifeVantage into a more brand-driven, consumer-focused company, supported by a modern digital platform and an expanding community of consumers and brand advocates.

At the same time, we are creating a more focused and efficient operating model and strengthening the underlying economics of the business. We have a lot of work to do, and building the company we envision will take time, but we have a differentiated foundation, a clear roadmap and a strong sense of urgency around execution.

The actions we are taking are designed to build a stronger, more relevant LifeVantage and create sustainable long-term value for our shareholders.”

First Quarter Fiscal 2027 Results

For the first quarter ended September 30, 2026, the Company reported revenue of $37.1 million, a 22.0% decrease compared to revenue of $47.6 million in the quarter ended September 30, 2025, including a $0.4 million, or 0.8% negative impact from foreign currency. Revenue in the Americas region decreased 22.2% to $29.0 million. Revenue in the Asia/Pacific & Europe region decreased 21.2% to $8.2 million, including a $0.4 million, or 3.9%, negative impact from foreign currency. The decrease in revenue was primarily driven by lower active accounts, reflecting impacts from the broader macro environment, as well as lower sales of the MindBody GLP-1 System^®. These declines were partially offset by sales of the LoveBiome product line, which the Company acquired in October 2025.

Gross profit for the quarter was $28.0 million, or 75.4% of revenue, compared to $37.8 million, or 79.5% of revenue, for the prior year period. The decrease in gross profit as a percentage of revenue was primarily due to an allowance for inventory obsolescence related to the MindBody GLP-1 System^®, along with increases in shipping and warehouse related expenses. Adjusted for the allowance for inventory obsolescence, non-GAAP gross profit was $29.0 million, or 78.2% of revenue.

Commissions and incentives expense for the quarter was $15.4 million, or 41.4% of revenue, compared to $20.7 million, or 43.5% of revenue, for the prior year period. The decrease in commissions and incentives expense as a percentage of revenue compared to the prior year period is primarily due to the timing and magnitude of promotional and incentive programs, changes in revenue mix, and changes in the mix of customers and independent consultants.

Selling, general and administrative (SG&A) expense for the quarter was $12.7 million, or 34.3% of revenue, compared to $14.9 million, or 31.2% of revenue, for the prior year period. The increase in SG&A expense as a percentage of revenue reflects the overall decrease in revenue.

Operating loss for the quarter was $0.1 million compared to operating income of $2.3 million for the prior year period. Adjusted non-GAAP operating income for the quarter was $0.9 million compared to adjusted non-GAAP operating income of $2.5 million for the prior year period.

Net loss for the quarter was $0.2 million, or $0.02 per diluted share, compared to net income of $2.2 million, or $0.17 per diluted share, for the prior year period. Adjusted non-GAAP net income for the quarter was $0.6 million, or $0.05 per diluted share, compared to adjusted non-GAAP net income of $2.3 million, or $0.18 per diluted share, in the prior year period.

Adjusted EBITDA was $1.9 million, or 5.2% of revenue, for the quarter, versus $3.9 million, or 8.2% of revenue, for the prior year period.

Balance Sheet & Liquidity

The Company generated $0.5 million of cash from operations during the three months ended September 30, 2026 compared to $2.3 million used in operations in the prior year period, primarily reflecting decreases in accounts receivable, inventory, and other accrued expenses. The Company’s cash and cash equivalents at September 30, 2026 were $13.7 million, compared to $14.9 million at June 30, 2026, and there was no debt outstanding.

Share Repurchase

During the quarter ended September 30, 2026, the Company did not repurchase any shares of its common stock. As of September 30, 2026, there was $58.5 million remaining under the $60 million share repurchase program.

About LifeVantage Corporation

LifeVantage Corporation (Nasdaq: LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim^® family of products, TrueScience^® Liquid Collagen, the MindBody GLP-1 System^®, the newest comprehensive gut activator from LoveBiome P84, the Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System®, as well as AXIO® nootropic and hydration energy drink mixes, the full TrueScience^® line of skin and hair care products, and Petandim^®, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.